Prospera Financial Services Inc Buys 1,158 Shares of Neurocrine Biosciences, Inc. $NBIX

Prospera Financial Services Inc grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 43.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,835 shares of the company’s stock after purchasing an additional 1,158 shares during the period. Prospera Financial Services Inc’s holdings in Neurocrine Biosciences were worth $482,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dodge & Cox lifted its holdings in Neurocrine Biosciences by 83.5% in the first quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock worth $612,129,000 after buying an additional 2,518,199 shares during the period. Wellington Management Group LLP lifted its stake in shares of Neurocrine Biosciences by 44.0% in the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after purchasing an additional 640,556 shares during the period. Swedbank AB boosted its position in shares of Neurocrine Biosciences by 5,078.9% during the first quarter. Swedbank AB now owns 429,697 shares of the company’s stock valued at $47,524,000 after purchasing an additional 421,400 shares in the last quarter. Braidwell LP grew its stake in Neurocrine Biosciences by 32.2% in the first quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock worth $131,827,000 after purchasing an additional 290,135 shares during the period. Finally, Nuveen LLC bought a new position in Neurocrine Biosciences in the first quarter worth $31,686,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. Guggenheim boosted their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Finally, Piper Sandler upped their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $170.53.

Neurocrine Biosciences Stock Up 0.5%

Shares of NASDAQ NBIX opened at $144.86 on Friday. The firm has a market cap of $14.44 billion, a P/E ratio of 34.66, a PEG ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.67. The company has a 50 day moving average of $142.64 and a 200 day moving average of $132.68.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The business had revenue of $794.90 million during the quarter, compared to analyst estimates of $746.61 million. During the same quarter last year, the company earned $1.81 EPS. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. As a group, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 300 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William H. Rastetter sold 18,000 shares of the stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the transaction, the director owned 40,360 shares in the company, valued at approximately $6,127,455.20. This trade represents a 30.84% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.